<DOC>
	<DOCNO>NCT01919827</DOCNO>
	<brief_summary>Clinical Trial Phase I , open , multicentric , non randomize , study escalate dos , evaluate safety feasibility treatment mesenchymal stem cell patient diagnosis idiopathic pulmonary fibrosis . Primary endpoint : The aim evaluate safety feasibility endobronchial administration mesenchymal autolog stem cell derive bone marrow ( BM-MSC ) patient mild-to-moderate idiopathic pulmonary fibrosis . Secondary endpoint : Assess possible effect infusion BM-MSC stop fall pulmonary function patient mild-to-moderate idiopathic pulmonary fibrosis .</brief_summary>
	<brief_title>Study Autologous Mesenchymal Stem Cells Treat Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Capacity sign inform consent express willing fulfill requirement study protocol study . 2 . The patient , researcher opinion , capable fulfill requirement trial . 3 . Male female patient , 30 80 year old , inclusive . 4 . Diagnosis idiopathic pulmonary fibrosis accord follow criterion , base ATS/ERS Guidelines : 1 . Definite probable usual interstitial pneumonia confirm surgical lung biopsy . 2 . In absence surgical lung biopsy , follow : . High resolution CT ( HRCT ) show definite finding idiopathic pulmonary fibrosis ( FPI ) : bibasal reticular opacity minimal ground glass opacity . ii . Absence known cause FPI include toxicity drug , environmental exposure connective tissue disease . iii . Pulmonary function test show ventilatory restrictive pattern and/or impair gas exchange ( FVC and/or DLCO &lt; 90 % predict ) 5 . FVC ≥ 50 % predict value ratio FEV1 FVC ≥ 0.70 . 6 . DLco ( correct hemoglobin ) ≥ 35 % predict value . 7 . Capability perform 6 minute walk test time inclusion . EXCLUSION CRITERIA : Any following : 1 . Current pregnancy lactation . 2 . Findings diagnostic interstitial pneumonia restrictive respiratory disease condition UIP . 3 . Obstructive pulmonary disease define FEV1/FVC &lt; 0,7 significant emphysema HRCT . 4 . Evidence sustain improvement FPI define improvement respiratory function test inclusion , observe &gt; =2 test year prior inclusion . 5 . Active recent respiratory infection ( le 60 day inclusion ) history frequent exacerbation IPF infectious cause ( 2/year last 2 year ) 6 . Hospitalization 60 day prior inclusion due acute exacerbation IPF . 7 . Chronic cardiac failure ( functional class NYHA III/IV ) leave ventricular ejection fraction &lt; 25 % . 8 . Chronically receive corticosteroid 10 mg prednisone equivalent , immunosuppressor antifibrotic agent , include pirfenidone , Dpenicillamine , colchicine , ciclosporin A , TNFalpha antagonists , imatinib , IFNgamma , azathioprine , cyclophosphamide , within 30 day prior inclusion . 9 . The patient require hemodialysis , peritoneal dialysis hemofiltration . 10 . History malignancy , exception skin squamous basocellular carcinoma cervix situ carcinoma treat successfully . 11 . History ethanol abuse within year prior inclusion 12 . The patient participate clinical trial include drug research product within 28 day prior baseline assessment . 13 . Comorbidities limit life expectancy le 12 month baseline assessment . 14 . Medical psychiatric condition serious active might interfere treatment study , assessment protocol fulfillment . 15 . Positive test HBsAg , HCV antibody , syphilis screening essay , HIV antibody screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Mesenchymal stem cell</keyword>
</DOC>